Wiseman, D., Laight, J., Boucher, R., Sankhalpara, C., Record, R., Byrne, J., Chowdhury, O., Culligan, D., Cunningham, N., Narayanan, S., Sellar, R., Batta, K., Raghavan, M., Searle, D. E., Cargo, C., Knapper, S., Kulasekararaj, A. (2025). ASTX727 delivers superior response rates and associated survival benefit versus hydroxycarbamide/best supportive care in CMML and other MDS/MPN overlap syndromes: First results from the Phase 2 UK multicenter randomized ammo trial. Blood. https://doi.org/10.1182/blood-2025-488